Journal article
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Abstract
PURPOSE: A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing models were constructed in the chemotherapy setting.
MATERIALS AND METHODS: Patient level data were used from phase I/II trials evaluating PD-L1 inhibitors following platinum based chemotherapy for metastatic urothelial carcinoma. The derivation data set consisted of 2 phase …
Authors
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G
Journal
Journal of Urology, Vol. 204, No. 6, pp. 1173–1179
Publisher
Wolters Kluwer
Publication Date
December 2020
DOI
10.1097/ju.0000000000001199
ISSN
0021-0005
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarboplatinCarcinoma, Transitional CellCisplatinClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDatasets as TopicFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingNomogramsRisk AssessmentTime FactorsUrologic Neoplasms